Synribo Approved for Chronic Myelogenous Leukemia
New Drugs , News / October 1, 2016

Synribo (omacetaxmie mepesuccinate) has been approved by the FDA to treat adults with chronic myelogenous leukemia (CML), a disease of the blood and bone marrow. It is intended for use in patients who cancer has progressed after treatment with at ...

Skip to toolbar